<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04461691</url>
  </required_header>
  <id_info>
    <org_study_id>POLAR-HF</org_study_id>
    <nct_id>NCT04461691</nct_id>
  </id_info>
  <brief_title>Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation With Heart Failure</brief_title>
  <acronym>POLAR-HF</acronym>
  <official_title>Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Josefs-Hospital Wiesbaden GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Josefs-Hospital Wiesbaden GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of atrial fibrillation (AF) and heart failure (HF) is common and implies a&#xD;
      poor prognosis. Pulmonary vein isolation is an established method for the treatment of&#xD;
      symptomatic AF in patients with normal heart function and has been shown to be more effective&#xD;
      than drug therapy. Recently, radiofrequency ablation has shown a positive effect in patients&#xD;
      with AF and HF. POLAR-HF has been designed to investigate efficacy and safety of cryoballoon&#xD;
      pulmonary vein isolation in patients with paroxysmal or persistent AF and severe HF (LVEF ≤&#xD;
      40%).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Measures (Number of recurrence)</measure>
    <time_frame>36 months</time_frame>
    <description>Number of subjects with recurrence of atrial fibrillation or re-ablation after a blanking Period of 90 days after the initial cryoablation procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Outcome Measures (number of safety events)</measure>
    <time_frame>36 months</time_frame>
    <description>2. Number of subjects with a primary safety event including a composite of death from any cause, stroke or transient ischemic attack and serious procedure-related adverse events (Major Bleeding by International Society on Thrombosis and Hemostasis (ISTH) criteria, pericardial effusion, cerebrovascular or systemic embolism, phrenic paresis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures (number of deaths)</measure>
    <time_frame>36 months</time_frame>
    <description>Number of all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures (procedural success)</measure>
    <time_frame>36 months</time_frame>
    <description>2. Incidence of acute procedural success assessed by successful isolation of all pulmonary veins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures (rehospitalization)</measure>
    <time_frame>36 months</time_frame>
    <description>3. Number of subjects reporting a first unplanned rehospitalization for cardiovasvular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures (procedure duration)</measure>
    <time_frame>36 months</time_frame>
    <description>4. Total procedure duration and left-atrial dwell time (in minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures (total time)</measure>
    <time_frame>36 months</time_frame>
    <description>5. Total fluoroscopy time (in minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures (total contrast use)</measure>
    <time_frame>36 months</time_frame>
    <description>6. Total contrast dye use (in milliliters)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Heart Failure</condition>
  <condition>Cryoballon Ablation</condition>
  <arm_group>
    <arm_group_label>Heart Failure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal cardiac function</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoballoon Pulmonary Vein Isolation</intervention_name>
    <description>Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.</description>
    <arm_group_label>Heart Failure</arm_group_label>
    <arm_group_label>Normal cardiac function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic paroxysmal or persistent atrial fibrillation&#xD;
&#xD;
          -  Patients with severe heart failure (LVEF ≤40%, assigned to heart failure group)&#xD;
&#xD;
          -  Patients with normal cardiac function (assigned to control group)&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Consent capacity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lack of consent capacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Ehrlich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Josefs-Hospital Wiesbaden GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Boehmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Josefs-Hospital Wiesbaden GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joachim Ehrlich, MD</last_name>
    <phone>+496111771201</phone>
    <email>jehrlich@joho.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Boehmer, MD</last_name>
    <phone>+496111771201</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Josefs-Hospital Wiesbaden GmbH</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Ehrlich, Prof. Dr.</last_name>
      <phone>+496111771201</phone>
      <email>jehrlich@joho.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Boehmer, Dr. med.</last_name>
      <phone>+496111771201</phone>
      <email>aboehmer@joho.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

